<DOC>
	<DOC>NCT01480336</DOC>
	<brief_summary>The purpose of this study is to learn if combination therapy with amiodarone and ranolazine (an approved drug for chest pain) can help prevent arrhythmias.</brief_summary>
	<brief_title>The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot</brief_title>
	<detailed_description />
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients with an ICD who were on a stable dose of amiodarone for the past 60 days Patients with a life expectancy of less than 6 months Patients with moderate or severe hepatic impairment (ChildPugh Classes B or C) or requiring hemodialysis. Pregnancy or lactation. Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Arrhythmia</keyword>
</DOC>